Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | P4HB | P07237 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7486767 | 0.71 | P2RX7 (0.35) | MAPTKMT2AMEN1 | |
| SCHEMBL15066985 | 0.67 | GLA (0.34) | GLATDP1 | |
| SCHEMBL21711071 | 0.67 | GLA (0.34) | GLATDP1 | |
| SCHEMBL4058771 | 0.64 | GLA (0.41) | GLATDP1KMT2AMEN1 | |
| SCHEMBL2037197 | 0.64 | P2RX7 (0.32) | — | |
| SCHEMBL12961208 | 0.63 | MAPT (0.36) | MAPTHTT | |
| SCHEMBL3507512 | 0.61 | — | — | |
| SCHEMBL30836750 | 0.61 | — | — | |
| SCHEMBL1587366 | 0.61 | — | — | |
| SCHEMBL20585233 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120189623-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-07-26 | — | — | US | disclosed |
| US-8129358-B2 | Substituted pyrazole and triazole compounds as KSP inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100034813-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100034813-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | CYP3A43, ABCG2, CYP3A7 | GLA 1640/4885TDP1 2098/4885MAPT 1700/4885 |
| US-20120189623-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | CYP3A5, GDI2, HDAC5 | GLA 189/4885TDP1 2967/4885MAPT 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.